Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) has received "Fast Track" designation from the US Food and Drug Administration.

7 Jan 2015

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced today that orphan drug designation has been granted by The US Department of Health and Human Services, The FDA Office of Orphan Products Development (OOPD) for the investigational medicinal product NiCord for the treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma and myelodysplastic syndrome (MDS).

6 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

TUM researchers discover new mechanism for regulating programmed cell death

Programmed cell death is a mechanism that causes defective and potentially harmful cells to destroy themselves. It serves a number of purposes in the body, including the prevention of malignant tumor growth. Now, researchers at Technische Universität München have discovered a previously unknown mechanism for regulating programmed cell death.

18 Dec 2014

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL).

10 Dec 2014

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL).

8 Dec 2014

Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

A therapy that liberates the immune system to attack cancer cells drove Hodgkin lymphoma (HL) into complete or partial remission in fully 87 percent of patients with resistant forms of the disease who participated in an early-phase clinical trial, investigators at Dana-Farber Cancer Institute and partnering institutions report in a study published today in the New England Journal of Medicine and simultaneously presented at the annual meeting of the American Society of Hematology in San Francisco.

7 Dec 2014

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Merck, known as MSD outside of Canada and the United States, announced today early study findings demonstrating that patients treated with pembrolizumab, the company's investigational anti-PD-1 cancer therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82).

7 Dec 2014

Nivolumab drug highly effective for Hodgkin's lymphoma

A phase I clinical trial of nivolumab found that the immune-boosting drug is a highly effective therapy for Hodgkin's lymphoma. The multi-institution study, led by Mayo Clinic, indicated that the drug was safe and led to an 87 percent response rate in patients who had failed on other treatments.

7 Dec 2014

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Novel treatments show promising results in patients with different hematologic disorders

In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders.

7 Dec 2014

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes.

7 Dec 2014

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate

Juno Therapeutics, Inc. announced today that the FDA has granted Orphan Drug Designation to its JCAR015 chimeric antigen receptor product candidate. The designation was granted for treatment of acute lymphoblastic leukemia. JCAR015 Phase I trials are currently underway at Juno's collaboration partner, Memorial Sloane Kettering Cancer Center.

18 Nov 2014

Newly-identified cancer cell fingerprints in the blood could help diagnose childhood cancer

Newly-identified cancer cell fingerprints in the blood could one day help doctors diagnose a range of children's cancers faster and more accurately, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference next week.

3 Nov 2014

Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Though therapies are in their nascent phase, sales of stem cell technologies are expected to show an annual increase of 16.2% over the 2010-2020 period, reaching an expected market value of nearly $1 billion, according to Kalorama Information's report, Stem Cell Therapeutics Markets.

31 Oct 2014

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company, has announced the launch of its lead product Rasuvo (methotrexate) injection for patients with rheumatoid arthritis (RA), poly-articular-course juvenile idiopathic arthritis (pJIA) and psoriasis in the U.S.

6 Oct 2014

Amgen seeks FDA approval for leukemia drug blinatumomab

Amgen today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration seeking approval for its investigational bispecific T cell engager (BiTE) antibody construct, blinatumomab.

22 Sep 2014

PET-CT more accurate than conventional CT in evaluating patients with follicular lymphoma

Positron emission tomography/computed tomography (PET-CT) is more accurate than conventional CT scanning in measuring response to treatment and predicting survival in patients with follicular lymphoma, and should be used routinely in clinical practice, according to new research published in The Lancet Haematology.

19 Sep 2014

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin).

8 Sep 2014

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Soligenix's SGX301 receives FDA 'Fast Track' designation for CTCL treatment

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

TUM researchers discover new mechanism for regulating programmed cell death

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Nivolumab drug highly effective for Hodgkin's lymphoma

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

Novel treatments show promising results in patients with different hematologic disorders

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate

Newly-identified cancer cell fingerprints in the blood could help diagnose childhood cancer

Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Amgen seeks FDA approval for leukemia drug blinatumomab

PET-CT more accurate than conventional CT in evaluating patients with follicular lymphoma

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Everything you should know about lymphoma eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Everything you should know about lymphoma eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in